Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Carmine, Valenza"'
Autor:
Lorenzo Gervaso, Davide Ciardiello, Giuliana Gregato, Lorenzo Guidi, Carmine Valenza, Liliana Ascione, Laura Boldrini, Samuele Frassoni, Chiara Alessandra Cella, Francesca Spada, Luigi Funicelli, Giuseppe De Roberto, Wanda Petz, Simona Borin, Marianna Alessandra Gerardi, Luca Bottiglieri, Darina Tamayo, Emilio Bertani, Uberto Fumagalli Romario, Vincenzo Bagnardi, Giuseppe Curigliano, Francesco Bertolini, Nicola Fazio, Maria Giulia Zampino
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: The management of locally advanced rectal cancer (LARC) relies on a multimodal approach. Neither instrumental work-up nor molecular biomarkers are currently available to identify a risk-adapted strategy. Objectives: We aim to investigate
Externí odkaz:
https://doaj.org/article/9f9c536bccb54df2b69506298ebbd4a9
Autor:
Carmen Criscitiello, Giuseppe Curigliano, Stefania Morganti, Gloria Pellizzari, Paolo Tarantino, Carmen Belli, Edoardo Crimini, Matteo Repetto, Angela Esposito, Marzia Locatelli, Ida Minchella, Eleonora Nicolo’, Luca Boscolo Bielo, Grazia Castellano, Pier Paolo Maria Berton Giachetti, Gabriele Antonarelli, Liliana Ascione, Carmine Valenza, Beatrice Taurelli Salimbeni
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d2f3c1f2945b4dd3bc96211b63e82c6a
Autor:
Carmine Valenza, Graziella Rizzo, Maria Ilenia Passalacqua, Laura Boldrini, Chiara Corti, Dario Trapani, Giuseppe Curigliano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line f
Externí odkaz:
https://doaj.org/article/270c304f22f740c2852ebf058959c8cd
Autor:
Carmine Valenza, Francesca Maria Porta, Alessandra Rappa, Elena Guerini-Rocco, Giuseppe Viale, Massimo Barberis, Filippo de Marinis, Giuseppe Curigliano, Chiara Catania
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3384-3392 (2021)
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Externí odkaz:
https://doaj.org/article/114bffc9f29743a2ab9cfc96b4d8a82b
Autor:
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFollowing the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate
Externí odkaz:
https://doaj.org/article/b82967c179b1415b8e47bb150aadac48
Autor:
Carmine Valenza, Pier Paolo Maria Berton Giachetti, Paola Zagami, Eleonora Nicolò, Dario Trapani, Laura Boldrini, Beatrice Taurelli Salimbeni, Liliana Ascione, Gabriele Antonarelli, Chiara Corti, Angela Esposito, Carmen Criscitiello, Nicola Fusco, Giuseppe Curigliano
Publikováno v:
Cancer Research. 83:P1-14
Background: Breast cancer (BC) with lymphangitic spread to the chest wall is a rare clinical entity affecting about 2% of pts, with poorer survival outcomes. A brisk immune infiltrate is typically reported, with up-regulation of inflammation and immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d85e8cc630c7848ee717b1d94690a8f3
https://doi.org/10.1158/1538-7445.sabcs22-p1-14-05
https://doi.org/10.1158/1538-7445.sabcs22-p1-14-05
Autor:
Chiara Corti, Gabriele Antonarelli, Carmine Valenza, Eleonora Nicolò, Hope Rugo, Javier Cortés, Nadia Harbeck, Lisa A. Carey, Carmen Criscitiello, Giuseppe Curigliano
Publikováno v:
European Journal of Cancer. 171:25-42
Several antibody-drug conjugates (ADCs) have been recently approved to treat solid tumours. Since ADCs seem to have activity in multiple malignancies sharing the expression of a specific antigen, they may be mirroring the experience of histology-agno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2af60ffd14b7721d8fd0ea2091d7765b
https://doi.org/10.1016/j.ejca.2022.04.039
https://doi.org/10.1016/j.ejca.2022.04.039
Publikováno v:
Expert Opinion on Investigational Drugs. 31:855-874
The treatment landscape of early triple-negative breast cancer (TNBC) has recently expanded after the Food and Drug Administration (FDA) approval of pembrolizumab in combination with neoadjuvant chemotherapy. The addition of this immune checkpoint in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58f6007da0d5fbf09dcc003dfb83da73
https://doi.org/10.1080/13543784.2022.2095260
https://doi.org/10.1080/13543784.2022.2095260
Autor:
Maria, Gion, Dario, Trapani, Alfonso, Cortés, Carmine, Valenza, Nancy, Lin, Javier, Cortés, Giuseppe, Curigliano
Publikováno v:
American Society of Clinical Oncology Educational Book. :82-92
Patients with HER2-positive breast cancer account for approximately 15% to 20% of all breast cancers and represent one of the most aggressive breast cancer subtypes. Survival rates of patients with metastatic disease have improved dramatically and pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b8d65764daf77b2cc60b798d4edd38
https://doi.org/10.1200/edbk_351222
https://doi.org/10.1200/edbk_351222
Autor:
Michele MONTORI, Francesco MARTINI, Federico DE BLASIO, Tiziana BUONO, Claudia QUATRACCIONI, Paola GUARDATI, Manuela CALZOLARI, Chiara ROSSI, Emanuele BENDIA, Stefano MENZO, Carmine VALENZA, Rinaldo PELLICANO, Luca MARONI, Antonio BENEDETTI
Publikováno v:
Minerva Gastroenterology. 69
Inflammatory Bowel Disease (IBD) patients on biological therapy are receiving vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). However, it is unclear if IBD therapy could influence the response to this vaccine. In a case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb8d5c7579b05327eb3dd8cfc78f259
https://doi.org/10.23736/s2724-5985.22.03134-5
https://doi.org/10.23736/s2724-5985.22.03134-5